Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.81 USD

67.81
4,294,477

-0.25 (-0.37%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $67.84 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (152 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic's (MDT) TYRX Envelope Study Results Encouraging

by Zacks Equity Research

Medtronic's (MDT) TYRX Envelope lowers infection risks and is cost-effective.

Trina Mukherjee headshot

3 MedTech Outperformers to Grab Amid September Pullback

by Trina Mukherjee

Let's grab these three stocks that have continued to show tremendous promise despite market volatility resulting from the coronavirus pandemic.

Zacks Equity Research

QIAGEN (QGEN) Completes Buyout of NeuMoDx, Expands Portfolio

by Zacks Equity Research

QIAGEN (QGEN) expands portfolio of automated testing solutions to address laboratory needs in almost any setting for molecular diagnostics via the completed buyout of NeuMoDx.

Zacks Equity Research

Bruker's Buyout of Canopy Biosciences Enhances Portfolio

by Zacks Equity Research

Bruker (BRKR) expands its multi-dimensional immune profiling by adding ChipCytometry tools via the acquisition of Canopy Biosciences.

Zacks Equity Research

CVS Health Retail Prescription Volume Grows Despite LTC Woes

by Zacks Equity Research

CVS Health's (CVS) consumer centric digital strategy has become even more relevant now.

Zacks Equity Research

Cardiovascular Systems Rides on Launches Amid Coronavirus Woes

by Zacks Equity Research

Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.

Zacks Equity Research

Boston Scientific Launches DBS System in Europe Post Approval

by Zacks Equity Research

Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.

Zacks Equity Research

Medtronic Receives FDA's Go Ahead for EFS Study on TTVR

by Zacks Equity Research

Medtronic (MDT) begins the FDA-approved EFS of Intrepid TTVR system following the receipt of the Breakthrough Device Designation from the regulatory authority.

Zacks Equity Research

National Vision Banks on Contact Lens Sales Amid Coronavirus Woes

by Zacks Equity Research

National Vision (EYE) sales bear the impact of unfavorable timing of unearned revenues.

Zacks Equity Research

Here's Why You Should Hold on to Medtronic Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) on robust segmental growth and strong ventilators sales.

Zacks Equity Research

Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement

by Zacks Equity Research

Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.

Zacks Equity Research

Henry Schein Partners MouthWatch to Grow in Teledentistry

by Zacks Equity Research

Henry Schien's (HSIC) customer base is likely to benefit from the Teledent platform.

Zacks Equity Research

QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test

by Zacks Equity Research

QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.

Zacks Equity Research

Abbott Banks on EPD, Nutrition Growth to Beat Coronavirus Woes

by Zacks Equity Research

Abbott (ABT) expects to register strong growth for the second half of 2020 within established pharmaceuticals (EPD).

Zacks Equity Research

Bruker Banks on Strategic Innovation Amid Coronavirus Crisis

by Zacks Equity Research

At Bruker's (BRKR) Germany campus, the company currently offers a pilot COVID-19 at work testing program for its factory workforce.

Zacks Equity Research

Henry Schein (HSIC) Enters Into New Dental Deal With Zyris

by Zacks Equity Research

Henry Schien (HSIC) is set to be the exclusive distributor of Zyris products like Isolite 3, Isovac 2, Isodry and the company's patented single-use Mouthpieces.

Zacks Equity Research

Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

Zacks Equity Research

Abbott Begins BTK Clinical Trial to Evaluate DRS Therapy

by Zacks Equity Research

Abbott (ABT) aims to provide a new treatment option for patients with CLI BTK, thus eliminating the need for any additional treatment.

Zacks Equity Research

Boston Scientific's Eluvia Gets CMS' Additional Reimbursement

by Zacks Equity Research

Boston Scientific (BSX) gains CMS' NTAP designation for its Eluvia stent system, thus providing additional reimbursement to Medicare beneficiaries suffering from PAD.

Zacks Equity Research

Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.

Zacks Equity Research

Medtronic (MDT) Plans Up to $475M of Annual Cost Savings

by Zacks Equity Research

Medtronic (MDT) expects its new operating model to help it become more focused in terms of speeding up research and developments.

Zacks Equity Research

ResMed (RMD) Launches First CPAP Nasal Mask With Memory Foam

by Zacks Equity Research

ResMed (RMD) adds another product to its line of easy-to-use, convenient and comfortable masks.

Zacks Equity Research

Phirbo's Product Mix Aids, Global Animal Health Business Ails

by Zacks Equity Research

Phirbo (PAHC) catered industries face issues like lack of processing availability and sudden drop in demand.

Zacks Equity Research

Medtronic's Pediatric Diabetes Device Gets Regulatory Nod

by Zacks Equity Research

MiniMed 770G is Medtronic's (MDT) MiniMed 670G System's upgraded version.

Zacks Equity Research

OMRI Clears NEOGEN's AquaPrime Peraside 15 as USDA Compliant

by Zacks Equity Research

NEOGEN (NEOG) completes organic certified water treatment program with the latest certification.